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Thrombosis in myeloproliferative 
neoplasms
Patients with myeloproliferative neoplasms 
(MPNs) exhibit a propensity for thrombo-
sis, which leads to significant morbidity and 
mortality (1, 2). Both arterial (e.g., stroke, 
myocardial infarction) and venous (e.g., pul-
monary embolism, deep vein thrombosis) 
systems can be affected, and unusual loca-
tions can be involved, such as the splanchnic 
vasculature. The prevalence of thrombot-
ic events has been reported to range from 
10% to 29% in essential thrombocythemia 
(ET) and 34% to 39% in polycythemia vera 
(PV) patients (3). In one population-based 
study, the incidence of arterial and venous 
thrombosis in the first 3 months after MPN 
diagnosis was 3 and 10 times higher, respec-
tively, compared with the incidence in indi-
viduals without MPN (4).
Established risk factors for thrombo-
sis in MPNs include older age and prior 
history of thrombosis (5). As the defining 
feature of PV is erythrocytosis, increased 
RBC mass presumably is a primary fac-
tor that drives thrombosis. Thus, current 
guidelines for PV patients recommend 
maintaining the hematocrit (HCT) at a 
level less than 45% (6). The importance 
of this specific target was validated by a 
study in which patients were randomized 
to two different treatment goals (HCT 
less than 45% versus HCT of 45%–50%) 
that demonstrated that the lower HCT 
goal associated with a lower likelihood of 
death from cardiovascular causes or major 
thrombotic events (7). In ET, the cardinal 
feature is excessive platelet production, 
although the degree of thrombocytosis 
(i.e., platelet count) has not been shown to 
correlate well with the risk of thrombosis 
(2). Current guidelines indicate that ET 
patients considered at high risk for throm-
bosis should be treated with cytoreductive 
therapy (most commonly hydroxyurea) to 
normalize platelet count (6).
A role for leukocytes in 
promoting MPN-associated 
thrombosis?
MPN patients also commonly exhibit leu-
kocytosis, and some studies have implicat-
ed leukocytosis as an independent risk fac-
tor for thrombosis (8–10). As noted above, 
cytoreductive therapies, such as hydroxy-
urea, are commonly used to reduce the 
HCT and/or platelet count in PV and ET 
patients. However, it has been speculated 
that an important benefit of hydroxyurea 
may be to lower the white blood count 
(WBC), thereby mitigating a potential con-
tribution of leukocytes to thrombus for-
mation (11). Neutrophils specifically have 
been recently recognized as integral to 
thrombus initiation and progression. Pro-
posed mechanisms by which leukocytes 
could contribute to thrombosis include the 
release of proteolytic enzymes by activat-
ed neutrophils, as well as increased CD11b 
expression, leading to stronger attach-
ment of leukocytes to the endothelium 
and platelets (1, 2). Abnormal generation 
of neutrophil extracellular traps (NETs), 
which contribute to coagulation and plate-
let aggregation, has also recently been 
linked to the MPN-associated mutation 
JAK2-V617F and thrombosis (12).
β1 and β2 integrin activation 
contributes to JAK2-V617F–
mediated thrombosis
β1 and β2 integrins are essential media-
tors of leukocyte adhesion to the endo-
thelium. In this issue, Edelmann and 
colleagues hypothesized that in MPNs, 
abnormal integrin function on leukocytes 
could contribute to thrombus formation 
(13). Granulocytes isolated from JAK2-
V617F knockin mice exhibited increased 
adhesion to VCAM1 and ICAM1, ligands 
for β1 and β2 integrin, respectively (Figure 
1A). These findings are consistent with 
recent studies from the same group show-
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Thrombosis is a major problem for patients with myeloproliferative 
neoplasms (MPNs). Leukocytes have long been speculated to contribute 
to thrombotic development in MPNs, but the exact role of these cells has 
not been fully elucidated. In this issue of the JCI, Edelmann and colleagues 
demonstrate that granulocytes from mice expressing an MPN-associated 
JAK2 mutation (JAK2-V617F) exhibit enhanced adhesion to VCAM1- and 
ICAM1-coated surfaces. The increased adhesion was shown to be mediated 
by β1 (VLA-4) and β2 integrins, which are activated via inside-out signaling 
induced by JAK2-V617F. In a murine thrombosis model, administration of 
neutralizing antibodies targeting VLA-4 and β2 integrin reduced thrombosis, 
suggesting the intriguing possibility that targeting these pathways could 
have clinical relevance for MPN.
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granulocyte adhesion to VCAM1 was also 
reduced following incubation with the 
PI3K inhibitor wortmannin. Similar reduc-
tions in adhesion were obtained with the 
Ca2+ and Mg2+ chelator BAPTA/AM, as well 
as with knockdown of the Ca2+-dependent 
enzyme CalDAG-GEFI, which is involved 
in conversion of Rap1-GDP to Rap1-GTP. 
Together, these findings suggest a role for 
PI3K and CalDAG-GEFI signaling in Rap1 
activation mediated by JAK2-V617F.
To determine the contribution of β1 and 
β2 integrin activation to JAK2-V617F–induced 
thrombosis Edelmann et al. utilized an inferi-
or vena cava (IVC) ligation model. Compared 
with JAK2-WT mice, JAK2-mutant mice 
exhibited a significant increase in thrombus 
size in response to partial IVC ligation that 
was dramatically reduced by injection of β1 
and β2 integrin–blocking antibodies (Fig-
ure 1A). These findings indicate that β1 and 
β2 integrins play an important role in JAK2-
V617F–driven thrombosis, and suggest that 
targeting β1 and β2 integrin activation could 
potentially be efficacious clinically.
Perspective
Together, these studies by Edelmann and 
colleagues highlight the role of neutrophils 
in MPN-associated thrombosis and shed 
light on the mechanism by which JAK2-
V617F activates β1and β2 integrins to pro-
mote thrombus formation. One outstand-
ing question not addressed in this study 
is whether inhibition of JAK2 with agents, 
such as ruxolitinib, might impact β1 and β2 
integrin activation driven by mutant JAK2. 
Regardless, the studies shown establish that 
blocking β1 and β2 integrin activation could 
mitigate JAK2-V617F–driven thrombosis. 
Agents that target various integrin subunits 
have shown promising activity in several 
inflammatory diseases, including multiple 
sclerosis and inflammatory bowel disease, 
although, integrin-targeting therapies have 
been associated with increased susceptibil-
ity to infection (15, 16). Whether targeting 
β1 and β2 integrin activation as a means of 
preventing thrombosis in MPNs is a viable 
strategy merits further exploration.
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ence in Rap1 expression is notable, since 
CALR-mutant MPN patients are known to 
be at lower risk for thrombosis compared 
with JAK2-mutant MPN patients.
Activation of Rap1-GTP is associated 
with translocation to the plasma mem-
brane, and JAK2-V617F expression was 
shown to promote Rap1 membrane relocal-
ization. Moreover, GGTI-2147, a geranyl-
geranyltransferase inhibitor that blocks the 
posttranslational modifications required 
for Rap1 activation and translocation to 
the plasma membrane, inhibited adhe-
sion of JAK2-mutant (but not JAK2-WT) 
granulocytes to VCAM1. JAK2- mutant 
ing that granulocytes from JAK2-mutant 
MPN patients have increased adhesion to 
VCAM1 (14).
Utilizing a conformation-specific anti-
body for β1 integrins, Edelmann and col-
leagues found that JAK2-V617F expression 
shifts β1 integrins from a closed, low-affinity 
confirmation to an open, high-affinity con-
formation (Figure 1A). This conformation 
change occurred via integrin inside-out-
side signaling that involves Rap1-GT-
Pase. In granulocytes from calreticulin- 
mutant (CALR-mutant) MPN patients, 
Rap1 was activated to a lesser degree than 
in JAK2-V617F granulocytes. This differ-
Figure 1. The myeloproliferative neoplasm–associated mutation JAK2-V617 promotes thrombus 
formation. (A) Neutrophils expressing JAK2-V617 have increased activation of β1 and β2 integrin, 
resulting in increased adhesion to VCAM and ICAM1 on the vascular endothelium and enhanced 
thrombus formation. JAK2-V617 enhances activation of Rap1, which then translocates to the plasma 
membrane, thereby inducing the inside-outside signaling that shifts β integrins from a closed, 
low-affinity confirmation to a high-affinity confirmation (inset). (B) Antibodies targeting β1 and β2 
integrin reduce neutrophil adhesion, resulting in decreased thrombus formation.
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